Torsten P. Vahl

Torsten P. Vahl

Auto-generated profile, based on publicly available information

Torsten P. Vahl

Division of Cardiothoracic Surgery, Columbia University Medical Center, 177 Fort Washington Avenue, 7GN-435, New York, NY 10032, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in The Lancet
Verified
Journal Article
Closed access
TVTorsten P Vahl
Torsten P Vahl
VTVinod H Thourani
Vinod H Thourani
RMRaj R Makkar
Raj R Makkar
NHNadira Hamid
Nadira Hamid
OKOmar K Khalique
Omar K Khalique
MLMartin B Leon
Martin B Leon

1 March 2016 in JACC
Verified
Journal Article
Closed access
TVTorsten P. Vahl
Torsten P. Vahl
SKSusheel K. Kodali
Susheel K. Kodali
MLMartin B. Leon
Martin B. Leon

5 March 2024 in Circulation
Verified
Journal Article
Closed access
SKSamir R. Kapadia
Samir R. Kapadia
AKAmar Krishnaswamy
Amar Krishnaswamy
BWBrian Whisenant
Brian Whisenant
SPSrinivasa Potluri
Srinivasa Potluri
VIVijay Iyer
Vijay Iyer
MLMartin B. Leon
Martin B. Leon
BACKGROUND: Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) and is associated with increased risk of bleeding and stroke. While left atrial appendage occlusion (LAAO) is approved as an alternative to anticoagulants for stroke prevention in patients with AF, placement of these devices in patients with severe aortic stenosis, or when performed at the same time as TAVR, has not been extensively studied. METHODS: WATCH-TAVR (WATCHMAN for Patients with AF Undergoing TAVR) was a multicenter, randomized trial evaluating the safety and effectiveness of concomitant TAVR and LAAO with WATCHMAN in AF patients. Patients were randomized 1:1 to TAVR + LAAO or TAVR + medical therapy. WATCHMAN patients received anticoagulation for 45 days followed by dual antiplatelet therapy until 6 months. Anticoagulation was per treating physician preference for patients randomized to TAVR + medical therapy. The primary noninferiority end point was all-cause mortality, stroke, and major bleeding at 2 years between the 2 strategies. RESULTS: The study enrolled 349 patients (177 TAVR + LAAO and 172 TAVR + medical therapy) between December 2017 and November 2020 at 34 US centers. The mean age of patients was 81 years, and the mean scores for CHA 2 DS 2 -VASc and HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) were 4.9 and 3.0, respectively. At baseline, 85.4% of patients were taking anticoagulants and 71.3% patients were on antiplatelet therapy. The cohorts were well-balanced for baseline characteristics. The incremental LAAO procedure time was 38 minutes, and the median contrast volume used for combined procedures was 119 mL versus 70 mL with TAVR alone. At the 24-month follow-up, 82.5% compared with 50.8% of patients were on any antiplatelet therapy, and 13.9% compared with 66.7% of patients were on any anticoagulation therapy in TAVR + LAAO compared with TAVR + medical therapy group, respectively. For the composite primary end point, TAVR + LAAO was noninferior to TAVR + medical therapy (22.7 versus 27.3 events per 100 patient-years for TAVR + LAAO and TAVR + medical therapy, respectively; hazard ratio, 0.86 [95% CI, 0.60–1.22]; P noninferiority <0.001). CONCLUSIONS: Concomitant WATCHMAN LAAO and TAVR is noninferior to TAVR with medical therapy in severe aortic stenosis patients with AF. The increased complexity and risks of the combined procedure should be considered when concomitant LAAO is viewed as an alternative to medical therapy for patients with AF undergoing TAVR. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03173534.

28 December 2019 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SCShmuel Chen
Shmuel Chen
BRBjorn Redfors
Bjorn Redfors
BOBrian P O’nEill
Brian P O’nEill
MCMarie-Annick Clavel
Marie-Annick Clavel
PPPhilippe Pibarot
Philippe Pibarot
BLBrian R Lindman
Brian R Lindman
B-type natriuretic peptide (BNP) is a cardiac neurohormone that is secreted in response to ventricular volume expansion and pressure overload. There are conflicting data regarding the association between BNP levels and outcomes after transcatheter aortic valve replacement (TAVR). We therefore sought to assess the association between baseline BNP and adverse outcomes in patients with symptomatic, severe aortic stenosis (AS), and left ventricular ejection fraction (LVEF) ≥50%, undergoing TAVR in the PARTNER 2 Trial and Registry. A total of 1782 patients were included in the analysis, and BNP was evaluated both as a continuous log-transformed value and by a priori categories: low (<50 pg/mL), normal (≥50 and <100 pg/mL), moderately elevated (≥100 and <400 pg/mL), or markedly elevated (≥400 pg/mL). Clinical outcomes from discharge to 2 years were compared between patients according to their baseline BNP level, using Kaplan–Meier event rates and multivariable Cox proportional hazards regression models. After adjustment, spline curves revealed a non-linear association between log-transformed BNP and all-cause and cardiovascular mortality in which both the lowest and highest values were associated with increased mortality. Two-year all-cause mortality rates for those with low (n = 86), normal (n = 202), moderately elevated (n = 885), and markedly elevated (n = 609) baseline BNP were 20.0%, 9.8%, 17.7%, and 26.1%, respectively. In adjusted models, compared to a normal baseline BNP, low [adjusted hazard ratio (HR) 2.6, 95% confidence interval (CI) 1.3–5.0, P-value 0.005], moderately elevated (adjusted HR 1.6, 95% CI 1.0–2.6, P-value 0.06), and markedly elevated (adjusted HR 2.1, 95% CI 1.3–3.5, P-value 0.003) BNP were associated with increased all-cause mortality, driven by cardiovascular mortality. In a large cohort of patients with severe symptomatic AS and preserved LVEF undergoing TAVR, all-cause and cardiovascular mortality rates at 2 years were higher in patients with low and markedly elevated BNP levels. https://clinicaltrials.gov/ unique identifier #NCT01314313, #NCT02184442, #NCT03222128, and #NCT03222141.

22 May 2020 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
SCShmuel Chen
Shmuel Chen
BRBjorn Redfors
Bjorn Redfors
ACAaron Crowley
Aaron Crowley
OBOri Ben-Yehuda
Ori Ben-Yehuda
MSMatthew Summers
Matthew Summers
MLMartin Leon
Martin Leon
Aims Heart failure (HF) hospitalization prior to transcatheter aortic valve replacement (TAVR) is associated with increased post‐procedural mortality. We sought to assess the association between recent (≤6 months) HF hospitalization and long‐term adverse outcomes in patients with symptomatic, severe aortic stenosis, undergoing TAVR in the PARTNER 2 trial and registries. Methods and results Intermediate to high or even prohibitive risk patients who underwent TAVR in the PARTNER 2 trial and registries were included in the analysis. Clinical outcomes at 30 days and 2 years were compared between patients according to whether they were recently hospitalized for HF, using Kaplan–Meier event rates and study‐stratified multivariable Cox proportional hazards regression models. A sensitivity analysis was conducted using propensity score matching. Of 3988 patients (99.8%) with available information on recent HF hospitalization, 1622 patients (40.7%) were hospitalized for HF symptoms during the 6 months prior to TAVR. After multivariable adjustments, recent HF hospitalization was associated with increased all‐cause mortality at 30 days [adjusted hazard ratio (HR) 1.63, 95% confidence interval (CI) 1.07–2.48, P = 0.02] and 2 years (adjusted HR 1.30, 95% CI 1.13–1.49, P = 0.0003), which was driven by increased cardiovascular mortality. Infective endocarditis rate at 2 years was also higher in patients with recent HF hospitalization (adjusted HR 2.35, 95% CI 1.38–4.01, P = 0.002). These results remained consistent when propensity score matching was used. Conclusion In a large cohort of patients with severe symptomatic aortic stenosis from the PARTNER 2 trial and registries, all‐cause and cardiovascular mortality as well as infective endocarditis rates at 2 years were higher in patients with recent HF hospitalization.

17 August 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
TOTakuya Ogami
Takuya Ogami
PKPaul Kurlansky
Paul Kurlansky
HTHiroo Takayama
Hiroo Takayama
YNYuming Ning
Yuming Ning
ZAZiad Ali
Ziad Ali
IGIsaac George
Isaac George
Background: Aortic stenosis is prevalent in end‐stage renal disease. Transcatheter aortic valve replacement (TAVR) is a plausible alternative for surgical aortic valve replacement. However, little is known regarding long‐term outcomes in patients with end‐stage renal disease who undergo TAVR. Methods and Results: We identified all patients with end‐stage renal disease who underwent TAVR from 2011 through 2016 using the United States Renal Data System. The primary end point was 5‐year mortality after TAVR. Factors associated with 1‐ and 5‐year mortality were analyzed. A total of 3883 TAVRs were performed for patients with end‐stage renal disease. Mortality was 5.8%, 43.7%, and 88.8% at 30 days, 1 year, and 5 years, respectively. Case volumes increased rapidly from 17 in 2011 to 1495 in 2016. Thirty‐day mortality demonstrated a dramatic reduction from 11.1% in 2012 to 2.5% in 2016 ( P =0.01). Age 75 or older (hazard ratio [HR], 1.14; 95% CI, 1.05–1.23 [ P =0.002]), body mass index <25 (HR, 1.18; 95% CI, 1.08–1.28 [ P <0.001]), chronic obstructive pulmonary disease (HR, 1.25; 95% CI, 1.1–1.35 [ P <0.001]), diabetes mellitus as the cause of dialysis (HR, 1.22; 95% CI, 1.11–1.35 [ P <0.001]), hypertension as the cause of dialysis (HR, 1.17; 95% CI, 1.06–1.29 [ P =0.004]), and White race (HR, 1.17; 95% CI, 1.06–1.3 [ P =0.002]) were independently associated with 5‐year mortality. Conclusions: Short‐term outcomes of TAVR in patients with end‐stage renal disease have improved significantly. However, long‐term mortality of patients on dialysis remains high.